# Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer

> **NCT07703163** · PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Solid Tumor
- SGLT 2 Inhibitors

## Interventions

- **DRUG:** Canagliflozin

## Key facts

- **NCT ID:** NCT07703163
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-10
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703163, "Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*